{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "QUIT", "name": "Achieve Life Sciences, Inc.", "url": "https://frontierpicks.com/dossiers/QUIT/", "json_url": "https://frontierpicks.com/dossiers/QUIT.json", "status": "DORMANT", "current_conviction": "MEDIUM", "archetype": { "code": "a5", "n": 5 }, "current_thesis": "AchieveRx (formerly Achieve Life Sciences) is modestly more likely than not to beat the S&P 500 over three months if its cytisinicline resubmission to the FDA lands in the fourth quarter of 2026; the refiling, due by about 31 December 2026, settles it.", "invalidation_trigger": "A daily close below $5.75, just above the 200-day average, which would show the market doubting the refiling timetable. The case also breaks if the resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.", "catalyst_date": null, "portfolio": null, "pick": null, "themes": [ "binary-catalyst-biotech" ], "tags": [], "sources": [], "caveats": [], "source_links": [ { "title": "AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates", "url": "https://www.biospace.com/press-releases/achieverx-reports-third-quarter-2026-financial-results-and-provides-business-updates", "date": null }, { "title": "AchieveRx Reports Q3 Results; Cytisinicline NDA Resubmission On Track For Q4 2026", "url": "https://www.rttnews.com/3712685/achieverx-reports-q3-results-cytisinicline-nda-resubmission-on-track-for-q4-2026.aspx", "date": null }, { "title": "November 10, 2026 - 8-K: Current report", "url": "https://ir.achieverx.com/sec-filings/all-sec-filings/content/0001193125-26-455404/achv-20261110.htm", "date": "2026-11-10" }, { "title": "AchieveRx stubs out old identity ahead of smoking cessation launch", "url": "https://www.fiercepharma.com/marketing/achieverx-stubs-out-old-identity-ahead-smoking-cessation-launch", "date": null }, { "title": "ACHIEVE LIFE SCIENCES, INC. - Form 8-K - FY2026", "url": "https://www.sec.gov/Archives/edgar/data/0000949858/000119312526344571/achv-ex99_1.htm", "date": "2026-08-11" } ], "evidence": [ { "claim": "Third-quarter 2026 report: NDA resubmission on track for the fourth quarter of 2026, potential FDA approval by the end of the second quarter of 2027; three commercial-scale stability batches completed at Adare.", "source": "AchieveRx third-quarter 2026 results release, 8-K exhibit 99.1", "as_of": "2026-11-10" }, { "claim": "Cash, cash equivalents and marketable securities were $201.5 million at 2026-09-30 versus $187.3 million at 2026-06-30, up mainly on warrant exercises.", "source": "AchieveRx third-quarter 2026 results release", "as_of": "2026-09-30" }, { "claim": "Third-quarter 2026 operating expenses were $20.5 million (research $6.2 million, general and administrative $14.3 million); net loss $12.1 million ($0.11 per share) including a $6.9 million non-cash warrant-liability gain; nine-month net loss $97.0 million.", "source": "AchieveRx third-quarter 2026 results release", "as_of": "2026-09-30" }, { "claim": "The FDA issued a complete response letter citing current Good Manufacturing Practice observations at a prior third-party manufacturing facility and incomplete final labeling; the company said no efficacy or safety deficiencies were identified.", "source": "Second-quarter 2026 results, 8-K exhibit 99.1", "as_of": "2026-06-20" }, { "claim": "ORCA-OL: four-week continuous abstinence rose from 25.5% (weeks 9–12) to 31.2% (weeks 49–52) among 479 adults; no new safety signals.", "source": "AchieveRx third-quarter 2026 results release; CHEST 2026 presentation", "as_of": "2026-10-21" }, { "claim": "Director Richard Alistair Stewart sold 20,626 shares on the open market at $8.49 on 2026-08-19.", "source": "SEC Form 4 filed 2026-08-21", "as_of": "2026-08-19" }, { "claim": "Private placement of up to $354 million: $180 million upfront from 49.4 million shares at $3.635, plus 49.5 million warrants at $3.51.", "source": "Company 8-K exhibit 99.1", "as_of": "2026-04-16" } ], "view_changes": [], "frame": { "as_of": "2026-11-14", "business": "AchieveRx develops cytisinicline, a plant-derived pill for smoking and vaping cessation, and has no approved product. It earns no product revenue and funds itself from share sales and warrant exercises; cash was $201.5 million on 2026-09-30.", "change": { "now": "On 2026-11-10 the company reported third-quarter results and said the cytisinicline resubmission remains on track for the fourth quarter of 2026, with potential FDA approval by the end of the second quarter of 2027.", "next": "Third-quarter operating expenses were $20.5 million (research $6.2 million, general and administrative $14.3 million) as launch staffing grows; cash of $201.5 million was up from $187.3 million on warrant exercises.", "linked": "The FDA's June 2026 complete response letter cited a prior third-party plant; the refiling names Adare Pharma Solutions as manufacturer. At launch the drug would face generic varenicline, the active ingredient in Pfizer's Chantix (PFE)." }, "priced_in": "No valuation multiples are stored for the company. The shares closed at $6.32 on 2026-11-13 against a company with no product revenue, $20.5 million of third-quarter 2026 operating expenses and $201.5 million of cash at 2026-09-30; that price holds only if the refiling lands on time and approval follows by mid-2027.", "links": { "customers": [], "suppliers": [], "competitors": [ { "ticker": "PFE", "url": null } ] } }, "filed_numbers": { "as_of": "2026-11-13", "sector": "Healthcare", "financials": { "status": "ok", "reason": null, "close_date": "2026-11-13", "latest_quarter": "2026-09-30", "figures": { "revenue": { "status": "not reported" }, "gross_margin": { "status": "not reported" }, "operating_margin": { "status": "not available" }, "pretax_income": { "status": "not reported" }, "net_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "four_quarters_end": "2026-09-30", "value_musd": -12.1, "four_quarters_musd": -111.7 }, "operating_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "first_end": "2025-12-31", "value_musd": -44 }, "capital_spending": { "status": "not available" }, "free_cash_flow": { "status": "not available" }, "diluted_share_change": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "base_end": "2025-09-30", "pct": 106.7 }, "cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 201.5 }, "debt": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 13, "composition": "convertible debt" }, "net_cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 188.5 }, "deferred_revenue": { "status": "not reported" }, "backlog": { "status": "not reported" }, "receivables": { "status": "not reported" }, "inventory": { "status": "not reported" }, "equity": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 180.7 }, "market_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-10", "basis_filed": "2026-11-10", "value_musd": 695.4 }, "enterprise_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-10", "basis_filed": "2026-11-10", "value_musd": 507 }, "ev_sales": { "status": "not available" }, "ev_ebit": { "status": "not available" }, "pe": { "status": "not meaningful" }, "pb": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-10", "basis_filed": "2026-11-10", "multiple": 3.8 }, "fcf_yield": { "status": "not available" } } }, "short_interest": { "status": "not available", "settlement": null, "published": null, "short_pct_of_outstanding": null, "days_to_cover": null, "change_pct": null }, "insiders": { "status": "not available yet", "as_of": null, "windows": [] } }, "body_markdown": "## Current Thesis\n\nAchieveRx's smoking-cessation drug, cytisinicline, can still reach FDA approval by mid-2027, and the shares are modestly more likely than not to beat the S&P 500 over the next three months if the refiling lands on schedule. A new drug application (NDA) resubmission naming Adare Pharma Solutions as finished-product manufacturer, planned for the fourth quarter of 2026, decides the case.\n\nThe FDA rejected the drug on 2026-06-20 over a former manufacturer's plant and incomplete labeling; the company says the agency identified no efficacy or safety deficiency. On 2026-11-10 the company reported third-quarter results and said the resubmission remains on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The same release said Adare had completed three commercial-scale stability batches.\n\nThe shares closed at $6.78 on 2026-11-09, the day of the rebrand to AchieveRx and the new QUIT symbol, and at $6.40 on 2026-11-10, the day of the report. The last close was $6.32 on 2026-11-13. The report confirmed the timetable without lifting the price.\n\n## Bull Case\n\n- **The timetable held at the third-quarter report.** On 2026-11-10 the company said the resubmission is on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The 2026-08-11 report had set the same dates.\n- **Adare has moved past the first batch.** The 2026-11-10 release says Adare completed three commercial-scale stability batches. On 2026-08-11 the company had reported one engineering batch.\n- **The rejection centered on the plant.** The complete response letter, received 2026-06-20, cited current Good Manufacturing Practice observations at a prior third-party facility and labeling not finished by the action date. The company said no efficacy or safety deficiencies were identified (second-quarter report, 2026-08-11).\n- **Cash rose in the quarter.** Cash, cash equivalents and marketable securities were $201.5 million on 2026-09-30, against $187.3 million on 2026-06-30, mainly on warrant exercises (2026-11-10 release).\n- **Quit rates rose over a year.** In the open-label ORCA-OL study, four-week continuous abstinence rose from 25.5% in weeks 9–12 to 31.2% in weeks 49–52 among 479 adults, with no new safety signals (2026-11-10 release; CHEST 2026 presentation, 2026-10-21).\n- **Launch staffing is in place.** Benjamin Halladay became chief financial officer on 2026-10-01 and Kaitlyn Tuson became senior vice president of marketing and communications on 2026-10-07 (company releases).\n\n## Bear Case\n\n- **Registration batches are not reported.** The 2026-11-10 release mentions stability batches at Adare and no registration batches, and lists a possible FDA pre-approval inspection among its risk factors.\n- **A dispute with Sopharma AD is disclosed.** The 2026-11-10 release cites the dispute without saying what it concerns.\n- **Overhead is rising with no revenue.** Third-quarter operating expenses were $20.5 million against $14.7 million a year earlier; general and administrative expense was $14.3 million against $9.4 million. The nine-month 2026 net loss was $97.0 million (2026-11-10 release).\n- **Cheap stock overhangs the shares.** The April 2026 placement sold 49.4 million shares at $3.635 and attached 49.5 million warrants at $3.51 (company 8-K, 2026-04-16). Warrant exercises add cash and new shares together. Director Richard Alistair Stewart sold 20,626 shares at $8.49 on 2026-08-19 (SEC Form 4).\n- **Generic competition shapes pricing.** Cytisinicline would launch against generic varenicline, which could restrain launch pricing and payer coverage in 2027.\n\n## Setup & Price Structure\n\nThe shares closed at $6.32 on 2026-11-13. That is 26.9% below the 52-week high of $8.64, reached intraday on 2026-09-03, and the 3-month change is –15.7%. The 52-week closing low was $2.65 on 2026-03-27.\n\nThe close sits below the 50-day average of $7.13 and above the 200-day average of $5.71, both as of 2026-11-13. Closes since the report were $6.40 on 2026-11-10, $6.45 on 2026-11-11, $6.29 on 2026-11-12 and $6.32 on 2026-11-13.\n\nThe market has priced in an on-time refiling but not an approval: the shares fell over three months while the company held its fourth-quarter 2026 refiling date at two successive quarterly reports. Across US stocks trading at least $5 million a day, the spread of 63-session returns was 27% in 2026 (standard deviation), so a three-month outcome for a single-catalyst name can land far from the index either way.\n\n## Catalyst Calendar\n\n- **~2026-12-31 (est.):** NDA resubmission for cytisinicline naming Adare as finished-product manufacturer. The company says the refiling is on track for the fourth quarter of 2026; it is the gating step toward approval in the first half of 2027, and a slip into 2027 delays the whole timeline.\n- **~2027-06-30 (est.):** Potential FDA approval of cytisinicline. The company anticipates approval by the end of the second quarter of 2027; approval would allow a US launch and open the 20-trading-day window for exercising the remaining April 2026 warrants.\n\n## What Would Change Our Mind\n\nA daily close below $5.75, just above the 200-day average, which would show the market doubting the refiling timetable. The case also breaks if the resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.\n\nThe risks this note tracks, each with what would confirm it:\n\n- The NDA resubmission slips past the fourth quarter of 2026. Confirmed by: A company update moving the refiling into 2027, or no resubmission announcement by the first quarterly report of 2027.\n- Manufacturing problems at Adare delay the filing or trigger a second complete response letter. Confirmed by: Disclosure of failed registration batches, missing stability work or adverse FDA inspection findings at Adare.\n- The dispute with Sopharma AD, cited in the 2026-11-10 release, affects supply or rights to cytisinicline. Confirmed by: A company filing or release describing the dispute's subject, a legal claim, or a change in the licence terms.\n- Placement investors and warrant holders sell into strength, or the company issues new shares. Confirmed by: Form 4 or 13D/G filings showing reduced stakes by lead investors, a registered resale, or a new share offering.\n- Rising overhead shortens the funding runway before launch. Confirmed by: Quarterly operating expenses above the $20.5 million of the third quarter of 2026 without a matching rise in cash from warrant exercises.\n- Generic varenicline restrains pricing and payer coverage at launch. Confirmed by: Restrictive formulary placement or a launch price below company expectations in 2027 commercial disclosures.\n\n## Correlation Notes\n\nThe shares trade on company-specific regulatory news. The complete response letter, the Adare transfer and the refiling date move them more than the broad market. Reported earnings also swing with the warrants, which are carried as a liability: the second quarter included a $48.7 million non-cash warrant charge, and the third quarter included a $6.9 million non-cash gain (company releases, 2026-08-11 and 2026-11-10). Headline losses therefore say little about the cash cost of running the business.", "first_seen": "2026-11-10", "last_analyzed": "2026-11-14T08:37:44+00:00", "last_synthesized": "2026-11-14", "date_modified": "2026-11-14", "license": "Content © FrontierPicks. Cite the canonical URL." }